Nintedanib Teva Gmbh (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby reducing fibroblast activity and angiogenesis. This dual antifibrotic and anti‑angiogenic action limits tissue scarring in lung disease and hampers tumor blood‑vessel formation in cancer.

The exact dose and schedule of Nintedanib are determined by the prescribing clinician based on the specific indication, patient characteristics and any concomitant therapies. Patients should follow the individualized regimen provided by their healthcare professional.

Nintedanib is contraindicated during pregnancy because it may cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended while taking Nintedanib, as safety for the infant has not been established.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow lung function decline, Nintedanib targets multiple tyrosine kinases and is also approved for certain cancers, whereas pirfenidone has a different safety profile, notably fewer gastrointestinal effects but more photosensitivity.

Nintedanib capsules should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture and direct sunlight. Do not refrigerate or freeze the product.

Nintedanib is taken orally as a capsule, usually with food to lessen gastrointestinal discomfort. Patients should swallow the capsule whole with water and follow the dosing schedule prescribed by their clinician.

Serious risks include liver injury (hepatotoxicity), significant bleeding events, and rare cardiovascular complications such as arterial thromboembolism. Patients should be monitored regularly for liver enzyme elevations and signs of bleeding, and any concerning symptoms should be reported promptly.

Nintedanib should not be used by pregnant women, individuals with severe liver impairment, or patients with uncontrolled bleeding disorders. Caution is also advised for those on strong CYP3A4 inhibitors or anticoagulants, and the drug is contraindicated in patients with known hypersensitivity to its components.